NRBO - Why Obesity-Drug Maker NeuroBo Stock Is Trading Higher | Benzinga
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) shares are trading higher Thursday after the company announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for DA-1726 for the treatment of obesity.
The Details:
NeuroBo announced that the FDA has cleared its IND application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The company plans to ...